Green, Heather L. http://orcid.org/0000-0003-1213-309X
Shen, Guannan
Franzen, Rose E.
Mcnamee, Marybeth
Berman, Jeffrey I.
Mowad, Theresa G.
Ku, Matthew
Bloy, Luke
Liu, Song
Chen, Yu-Han
Airey, Megan
McBride, Emma
Goldin, Sophia
Dipiero, Marissa A.
Blaskey, Lisa
Kuschner, Emily S.
Kim, Mina
Konka, Kimberly
Roberts, Timothy P. L.
Edgar, J. Christopher
Funding for this research was provided by:
National Institutes of Health (R01DC008871, R01MH107506, R21MH098204, R21NS090192)
National Institute of Child Health and Human Development (R01HD093776, 5U54HD086984)
Nancy Lurie Marks Family Foundation (Sensory Consortium Grant)
Article History
Accepted: 22 July 2022
First Online: 12 August 2022
Declarations
:
: Dr. Berman reports a consultancy with McGowan Associates. Dr. Roberts declares his position on the advisory boards of (1) CTF MEG, (2) Ricoh, (3) Spago Nano Medicine, (4) Avexis Inc., (5) Acadia Pharmaceuticals and equity interests in (1) Prism Clinical Imaging and (2) Proteus Neurodynamics. Dr. Roberts and Dr. Edgar also declare intellectual property relating to the potential use of electrophysiological markers for treatment planning in clinical ASD. Dr. Blaskey reports a consultancy with KBT Technologies. No other authors have anything to disclose.
: This study was approved by the local Institutional Review Board, and all families gave written informed consent. When competent to do so, children over 7 years of age gave verbal assent to participate.
: Not applicable.
Free to read: This content has been made available to all.